By Emeritus Professor John Whitelock

Journal articles

Patel VN; Knox SM; Likar KM; Lathrop CA; Hossain R; Eftekhari S; Whitelock J; Elkin M; vlodavsky I; Hoffman MP, 2007, 'Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibilar gland branching morphogenesis', Development (Cambridge), 134, pp. 4177 - 4186, http://dx.doi.org/10.1242/dev.011171

Knox SM; Whitelock J, 2006, 'Perlecan: how does one molecule do so many things?', CMLS - Cellular and Molecular Life Sciences, 63, pp. 2435 - 2445, http://dx.doi.org/10.1007/s00018-006-6162-z

Sher I; Zisman-Rozen S; Eliahu L; Whitelock J; Maas-Szabowski N; Yamada Y; Breitkreutz D; Fusenig N; Arikawa-Hirasawa E; Lozzo R; Bergman R; Ron D, 2006, 'Targeting perlecan in human keratinocytes reveals novel roles for perlecan in epidermal formation', The Journal of Biological Chemistry, 281, pp. 5178 - 5187, http://dx.doi.org/10.1074/jbc.M509500200

Lord MS; Cousins B; Doherty P; Whitelock J; Simmons A; Williams R; Milthorpe BK, 2006, 'The effect of silica nanoparticulate coatings on serum protein adsorption and cellular response', Biomaterials, 27, pp. 4856 - 4862, http://dx.doi.org/10.1016/j.biomaterials.2006.05.037

DeCarlo A; Whitelock J, 2006, 'The role of heparan sulfate and perlecan in bone-regenerative procedures', Journal of Dental Research, 85, pp. 122 - 132, http://dx.doi.org/10.1177/154405910608500203

Melrose J; Roughley P; Knox SM; Smith S; Lord MS; Whitelock J, 2006, 'The structure, location and function of perlecan, a prominent pericellular proteoglycan of foetal, postnatal and mature hyaline cartilages', The Journal of Biological Chemistry, 281, pp. 36905 - 36914, http://dx.doi.org/10.1074/jbc.M608462200

Whitelock JM; Iozzo RV, 2005, 'Heparan sulfate: A complex polymer charged with biological activity', Chemical Reviews, 105, pp. 2745 - 2764, http://dx.doi.org/10.1021/cr010213m

Melrose J; Smith S; Cake M; Read R; Whitelock J, 2005, 'Comparative spatial and temporal localisation of perlecan, aggrecan and type I, II and IV collagen in the ovine meniscus: an ageing study', Histochemistry and Cell Biology, 124, pp. 225 - 235, http://dx.doi.org/10.1007/s00418-005-0005-0

Whitelock J; Iozzo R, 2005, 'Heparan sulfate: a complex polymer charged with biological activity', Chemical Reviews, 105, pp. 2745 - 2764, http://dx.doi.org/10.1002/chin.200542258

Melrose J; Smith S; Cake M; Read R; Whitelock J, 2005, 'Perlecan displays variable spatial and temporal immunolocalisation patterns in the articular and growth plate cartilages of the ovine stifle joint', Histochemistry and Cell Biology, 123, pp. 561 - 571, http://dx.doi.org/10.1007/s00418-005-0789-y

Knox SM; Fosang A; Last K; Melrose J; Whitelock J, 2005, 'Perlecan from human epithelial cells is a hybrid heparan/chondroitin/keratan sulfate proteoglycan', FEBS Letters, 579, pp. 5019 - 5023, http://dx.doi.org/10.1016/j.febslet.2005.07.090

Karlsson N; Schulz B; Packer N; Whitelock J, 2005, 'Use of graphitised carbon negative ion LC-MS to analyse enzymatically digested glycosaminoglycans', Journal of Chromatography B - Analytical Technologies in the Biomedical and Life Sciences, 824, pp. 139 - 147, http://dx.doi.org/10.1016/j.jchromb.2005.07.014

Chau NC; Whitelock J; Poole-Warren L, 2004, 'Proteoglycans and the bioengineering of vascular grafts: Perlecan, a non-thrombogenic treatment', Transactions - 7th World Biomaterials Congress, pp. 400

Melrose J; Smith ST; Whitelock J, 2004, 'Perlecan immunolocalizes to perichondrial vessels and canals in humanfetal cartilaginous primordia in early vascular and matrix remodelingevents associated with diarthrodial joint development', Journal of Histochemistry and Cytochemistry, 52, pp. 1405 - 1413, http://dx.doi.org/10.1369/jhc.4A6261.2004

Garl P; Wenzlau J; Walker H; Whitelock J; Costell M; Weiser-Evans M, 2004, 'Perlecan-induced suppression of smooth muscle cell proliferation is mediated through increased activity of the tumor suppressor PTEN', Circulation Research, 94, pp. 175 - 183, http://dx.doi.org/10.1161/01.RES.0000109791.69181.B6

Melrose J; Smith S; Ghosh P; Whitelock J, 2003, 'Perlecan, the multidomain heparan sulfate proteoglycan of basement membranes, is also a prominent component of the cartilaginous primordia in the developing human fetal spine', Journal of Histochemistry and Cytochemistry, 51, pp. 1331 - 1341, http://dx.doi.org/10.1177/002215540305101010

Walker HA; Whitelock JM; Garl PJ; Nemenoff RA; Stenmark KR; Weiser-Evans MCM, 2003, 'Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling', Molecular Biology of the Cell, 14, pp. 1941 - 1952, http://dx.doi.org/10.1091/mbc.E02-08-0508

Underwood PA; Whitelock JM; Bean PA; Steele JG, 2002, 'Effects of base material, plasma proteins and FGF2 on endothelial cell adhesion and growth', Journal of Biomaterials Science, Polymer Edition, 13, pp. 845 - 862, http://dx.doi.org/10.1163/156856202320401924

Whitelock JM; Iozzo RV, 2002, 'Isolation and purification of proteoglycans', Methods in Cell Biology, 2002, pp. 53 - 67, http://dx.doi.org/10.1016/S0091-679X(02)69007-7

Melrose J; Smith S; Knox S; Whitelock J, 2002, 'Perlecan, the multidomain HS-proteoglycan of basement membranes, is a prominent pericellular component of ovine hypertrophic vertebral growth plate and cartilaginous endplate chondrocytes', Histochemistry and Cell Biology, 118, pp. 269 - 280, http://dx.doi.org/10.1007/s00418-002-0449-4

Knox SM; Merry C; Stringer S; Melrose J; Whitelock J, 2002, 'Not all perlecans are created equal: Interactions with fibroclast growth factor (FGF) 2 and FGF receptors', The Journal of Biological Chemistry, 277 (17), pp. 14657 - 14665

Knox S; Melrose J; Whitelock J, 2001, 'Electrophoretic, biosensor, and bioactivity analyses of perlecans of different cellular origins', Proteomics, 1, pp. 1534 - 1541, http://dx.doi.org/10.1002/1615-9861(200111)1:12<1534::AID-PROT1534>3.0.CO;2-A

Whitelock J, 2001, 'Purification of perlecan from endothelial cells.', Methods in molecular biology (Clifton, N.J.), 171, pp. 27 - 34

Underwood PA; Bean PA; Mitchell SM; Whitelock JM, 2001, 'Specific affinity depletion of cell adhesion molecules and growth factors from serum', Journal of Immunological Methods, 247, pp. 217 - 224, http://dx.doi.org/10.1016/S0022-1759(00)00327-6

Whitelock J; Bean P; Knox S; Graham L; Mitchell S; Underwood A, 2000, 'The purification and characterization of recombinant domain I of perlecan expressed in HEK-293 cells', Second Smith and Nephew International Symposium - Tissue Engineering 2000: Advances in Tissue Engineering, Biomaterials and Cell Signalling, pp. 112

Mongiat M; Taylor K; Otto J; Aho S; Uitto J; Whitelock JM; Iozzo RV, 2000, 'The protein core of the proteoglycan perlecan binds specifically to fibroblast growth factor-7', Journal of Biological Chemistry, 275, pp. 7095 - 7100, http://dx.doi.org/10.1074/jbc.275.10.7095

Whitelock JM; Graham LD; Melrose J; Murdoch AD; Iozzo RV; Anne Underwood P, 1999, 'Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells', Matrix Biology, 18, pp. 163 - 178, http://dx.doi.org/10.1016/S0945-053X(99)00014-1

Graham LD; Whitelock JM; Underwood PA, 1999, 'Expression of human perlecan domain I as a recombinant heparan sulfate proteoglycan with 20-kDa glycosaminoglycan chains', Biochemical and Biophysical Research Communications, 256, pp. 542 - 548, http://dx.doi.org/10.1006/bbrc.1999.0377

Whitelock J; Mitchell S; Underwood PA, 1999, 'Erratum: The effect of human endothelial cell-derived proteoglycans on human smooth muscle cell growth (Cell Biology International (1997) 21 (181-189))', Cell Biology International, 23, pp. 451, http://dx.doi.org/10.1006/cbir.1999.0353

Underwood PA; Mitchell SM; Whitelock JM, 1998, 'Heparin fails to inhibit the proliferation of human vascular smooth muscle cells in the presence of human serum', Journal of Vascular Research, 35, pp. 449 - 460, http://dx.doi.org/10.1159/000025616

Sharma B; Handler M; Eichstetter I; Whitelock JM; Nugent MA; Iozzo RV, 1998, 'Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo', Journal of Clinical Investigation, 102, pp. 1599 - 1608, http://dx.doi.org/10.1172/JCI3793

Underwood PA; Bean PA; Whitelock JM, 1998, 'Inhibition of endothelial cell adhesion and proliferation by extracellular matrix from vascular smooth muscle cells: Role of type V collagen', Atherosclerosis, 141, pp. 141 - 152, http://dx.doi.org/10.1016/S0021-9150(98)00164-6

Melrose J; Whitelock J; Xu Q; Ghosh P, 1998, 'Pathogenesis of abdominal aortic aneurysms: Possible role of differential production of proteoglycans by smooth muscle cells', Journal of Vascular Surgery, 28, pp. 676 - 686, http://dx.doi.org/10.1016/S0741-5214(98)70094-1

Graham LD; Hayward IP; Fitzgerald M; Whitelock JM; Bingley JA; Campbell JH; Underwood PA, 1997, 'Inhibition of phenotype modulation, growth, and migration of vascular smooth muscle cells by a guanosine-rich 30-mer phosphorothioate oligodeoxynucleotide', Cell Biology International, 21, pp. 585 - 594, http://dx.doi.org/10.1006/cbir.1997.0189

Whitelock J; Mitchell S; Underwood PA, 1997, 'The effect of human endothelial cell-derived proteoglycans on human smooth muscle cell growth', Cell Biology International, 21, pp. 181 - 189, http://dx.doi.org/10.1006/cbir.1996.0125

Whitelock JM; Murdoch AD; Iozzo RV; Underwood PA, 1996, 'The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases', Journal of Biological Chemistry, 271, pp. 10079 - 10086, http://dx.doi.org/10.1074/jbc.271.17.10079

Lyons JG; Birkedal-Hansen B; Pierson MC; Whitelock JM; Birkedal-Hansen H, 1993, 'Interleukin-1β and transforming growth factor-α/epidermal growth factor induce expression of Mr 95,000 type IV collagenase/gelatinase and interstitial fibroblast-type collagenase by rat mucosal keratinocytes', Journal of Biological Chemistry, 268, pp. 19143 - 19151

Gibbins JR; Paine ML; Whitelock JM; O'Grady RL; Kefford RF, 1993, 'Unregulated and Independent Expression of Collagenase and Transin Related to Tumor Progression', Journal of the National Cancer Institute, 85, pp. 1425 - 1427, http://dx.doi.org/10.1093/jnci/85.17.1425

WHITELOCK JM; PAINE ML; GIBBINS JR; KEFFORD RF; O'GRADY RL, 1993, 'Multiple levels of post‐transcriptional regulation of collagenase (matrix metalloproteinase 1) in an epithelial cell line', Immunology and Cell Biology, 71, pp. 39 - 47, http://dx.doi.org/10.1111/j.1440-1711.1993.tb03386.x

Nethery A; Giles I; Jenkins K; Jackson C; Brooks P; Burkhardt D; Ghosh P; Whitelock J; O'Grady RL; Welgus HG; Schrieber L, 1992, 'The chondroprotective drugs, arteparon and sodium pentosan polysulphate, increase collagenase activity and inhibit stromelysin activity in vitro', Biochemical Pharmacology, 44, pp. 1549 - 1553, http://dx.doi.org/10.1016/0006-2952(92)90471-T

Whitelock JM; O'Grady RL, 1992, 'The production of collagenase and an inhibitor of collagenase by rat mammary carcinoma cells.', Matrix (Stuttgart, Germany). Supplement, 1, pp. 413 - 414

Whitelock JM; O'Grady RL; Gibbins JR, 1991, 'Interstitial collagenase (matrix metalloproteinase 1) associated with the plasma membrane of both neoplastic and nonneoplastic cells', Invasion and Metastasis, 11, pp. 139 - 148

Whitelock JM; O'Grady RL; Gibbins JR, 1991, 'The identification, purification and characterisation of an inhibitor of collagenase (20K) produced by neoplastic epithelial cells', BBA - General Subjects, 1073, pp. 107 - 113, http://dx.doi.org/10.1016/0304-4165(91)90189-N

Whitelock JM; O'Grady RL; Gibbins JR, 1991, 'Interstitial collagenase (matrix metalloproteinase 1) associated with the plasma membrane of both neoplastic and nonneoplastic cells', Invasion and Metastasis, 11, pp. 139 - 148

Whitelock JM; O'Grady RL; Lyons JG, 1989, 'Immunolocalization of collagenase in neoplastic epithelial cells', Immunology and Cell Biology, 67, pp. 349 - 357, http://dx.doi.org/10.1038/icb.1989.51

Back to profile page